Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Tilavonemab in PSP
NCT03413319Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tilavonemab in progressive supranuclear palsy (PSP), sponsored by AbbVie Inc. Primary endpoint: Adverse Events up to 29 months. Started Apr 2018; status: completed.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03413319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03413319.